Antigrippin-anvi capsules №20

Mechanism of action

Analgesic antipyretic combined composition.
Acetylsalicylic acid has analgesic, antipyretic and anti-inflammatory effects; inhibits platelet aggregation.
Ascorbic acid (vitamin C) plays an important role in the regulation of redox processes, carbohydrate metabolism, blood clotting, tissue regeneration, contributes to an increase in body resistance.
Rutin normalizes and supports the structure, elasticity, function and permeability of blood vessels, and also has antioxidant, anti-inflammatory and antiallergic action.
Metamizole sodium has analgesic, antipyretic and weak anti-inflammatory action, the mechanism of which is associated with inhibition of prostaglandin synthesis.
Diphenhydramine has antiallergic, anti-edema effect. Reduces vascular permeability, eliminates swelling and hyperemia of the nasal mucosa, reduces tickling in the throat and the manifestations of allergic reactions from the upper respiratory tract.
Calcium gluconate is a regulator of Calcium and phosphorus metabolism, reduces vascular permeability. In allergic diseases or conditions, its combined use with antihistamines is recommended.

Data on the pharmacokinetics of the drug Antigrippin-anvi is not provided.

Indications and usage

- symptomatic therapy of influenza, SARS in adults and adolescents over 15 years of age.

Drug is prescribed adults and adolescents over 15 years old 2 capsules per reception: 1 green capsule and 1 white capsule.
The duration of treatment is 3-5 days until the symptoms of the disease disappear.
Capsules are ingested after a meal, drinking water. The patient should be warned that in the absence of improvement in health, taking the drug should be stopped and consult a doctor.

Adverse reactions

Gastrointestinal: anorexia, nausea, vomiting, gastralgia, diarrhea, erosive and ulcerative lesions of the gastrointestinal tract, Gastrointestinal bleeding, hepatic failure.
Cardiovascular: increased blood pressure, tachycardia.
Allergic reactions: skin rash, angioedema, bronchospasm (with a tendency to bronchospasm may provoke an attack).
Side effects observed with prolonged use of the drug (more than 7 days).
Hemic and lymphatic: thrombocytopenia, agranulocytosis, leukopenia.
From the side of the central nervous system: dizziness, headache, visual disturbances, tinnitus, deafness.
From the blood coagulation system: reduction of platelet aggregation, hypocoagulation, hemorrhagic syndrome (including nosebleeds, bleeding gums, purpura).
Allergic reactions: anaphylactic shock, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell's syndrome).
Urogenital: kidney damage with papillary necrosis, renal dysfunction, oliguria, anuria, protenuria, interstitial nephritis, urine staining in red due to the release of the metabolite.
Other: in adolescents, Reye's syndrome (hyperpyrexia, metabolic acidosis, disorders of the nervous system and psyche, vomiting, abnormal liver function).
The patient should be warned that all side effects, including those not mentioned above, should be reported to your doctor and stop taking the drug.

Contraindications

- tendency to bleed;
- inhibition of blood formation (agranulocytosis, neutropenia, leukopenia);
- hemorrhagic diathesis (hemophilia, Willebrand disease, telangiectasia, hypoprothrombinemia, thrombocytopenia, thrombocytopenic purpura);
- vitamin K deficiency;
- bronchial asthma and diseases accompanied by bronchospasm;
- severe abnormal liver function;
- portal hypertension;
- Severe renal dysfunction;
- deficiency of glucose-6-phosphate dehydrogenase (including with hereditary hemolytic anemia due to a deficiency of this enzyme);
- stratifying aortic aneurysm;
- hypercalcemia (the concentration of calcium ions should not exceed 12 mg% or 6 meq / l);
- hypercalciuria;
- Nephrolithiasis (calcium);
- sarcoidosis;
- glycoside intoxication (risk of arrhythmia);
- pregnancy;
- lactation (breastfeeding);
- children's and teenage age up to 15 years;
- hypersensitivity to the drug.

Pregnancy and breastfeeding

The drug is contraindicated for use in pregnancy. If necessary, the appointment during lactation should stop breastfeeding for the period of use of the drug.
Acetylsalicylic acid has a teratogenic effect: when applied in the first trimester of pregnancy leads to the development of splitting of the upper palate; in the third trimester - to premature closure of the arterial duct in the fetus, which causes hyperplasia of the pulmonary vessels and hypertension in the vessels of the pulmonary circulation, and inhibition of labor (due to inhibition of prostaglandin synthesis).
Acetylsalicylic acid is excreted in breast milk, which increases the risk of bleeding in a child due to dysfunction of platelets.

Special notes

Carefully prescribe the drug for hyperuricemia, urate nephrolithiasis, gout, gastric ulcer and duodenal ulcer (history), decompensated heart failure.
With prolonged use of the drug is necessary to control the picture of peripheral blood and laboratory parameters of the functional state of the liver.
Since Acetylsalicylic acid has an anti-aggregation effect, the patient, if he is to undergo surgery, must notify the doctor in advance about taking the drug.
Acetylsalicylic acid in low doses reduces the excretion of uric acid, which can in some cases provoke an attack of gout.
The administration of Ascorbic acid to patients with rapidly proliferating and intensely metastatic tumors can aggravate the process.
In patients with asthma and hay fever when taking the drug may develop hypersensitivity reactions.
In connection with the stimulating effect of ascorbic acid on the synthesis of corticosteroid hormones, it is necessary to monitor the kidney function and blood pressure.
It is not recommended to prescribe a drug with anticoagulants, GCS, ticlopidine, uricosuric and antihypertensive agents.
Ascorbic acid may distort the results of various laboratory tests (determination of glucose, bilirubin and activity of hepatic transaminases, LDH in plasma).
Radiocontrast agents, colloidal blood substitutes and penicillin should not be used during the administration of metamizole sodium.
Against the background of the use of the drug should avoid alcohol because of the increased risk of gastrointestinal bleeding.
Use in pediatrics
The drug is not prescribed as an antipyretic in children under the age of 15 years with acute respiratory viral diseases due to the risk of Reye's syndrome (encephalopathy and acute fatty liver with acute development of liver failure).
Influence on ability to drive motor transport and control mechanisms
During the period of use of the drug should refrain from engaging in potentially hazardous activities that require increased attention and speed of psychomotor reactions.

Symptoms: nausea, vomiting, stomach pain, sweating, pallor of the skin, tachycardia; with a slight overdose - ringing in the ears; in severe overdose - drowsiness, collapse, convulsions, bronchospasm, difficulty breathing, anuria, bleeding, progressive respiratory paralysis, respiratory acidosis.
Treatment: artificial vomiting, gastric lavage, the appointment of saline laxatives, Activated carbon ; with the appearance of convulsions - in / in the introduction of diazepam and barbiturates; if necessary - conducting forced diuresis, hemodialysis.

Drug Interactions

With the simultaneous use of Antigrippin-anvi enhances the action of Heparin, indirect anticoagulants, reserpine, steroid hormones and hypoglycemic agents.
With the simultaneous use of Antigrippin-anvi reduces the effectiveness of spironolactone, Furosemide, antihypertensive and uricosuric drugs.
Antigrippin-anvi enhances the side effects of GCS, sulfonylurea derivatives, Methotrexate, non-narcotic analgesics and NSAIDs.
With the simultaneous use of Antigrippin-anvi with barbiturates, antiepileptic drugs, zidovudine, rifampicin and ethanol-containing drugs increases the risk of hepatotoxic action.
Ascorbic acid improves intestinal absorption of iron preparations.
Tricyclic antidepressants, oral contraceptives and Allopurinol violate the metabolism of metamizole in the liver and increase its toxicity.
The simultaneous use of metamizole with cyclosporine reduces the level of the latter in the blood plasma.
Sedatives and tranquilizers enhance the analgesic effect of metamizole.
When used simultaneously with metamizole, thiamazole and melphalan increase the risk of leukopenia.

The drug should be stored in a dry, protected from light, out of reach of children at room temperature. Shelf life - 2 years.
Pharmacy sales terms
The drug is approved for use as a means of OTC.